Related Experiment Video
Updated: Aug 2, 2025

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Innate Immunity System in Patients With Cardiovascular and Kidney Disease
Carmine Zoccali1, Francesca Mallamaci2
1Renal Research Institute New York and Institute of Molecular Biology and genetics (BIOGEM), Ariano Irpino, Italy and Associazione Ipertensione, Nefrologia, Trapianto (IPNET), Reggio Calabria Italy (C.Z.).
Insights
Chronic kidney disease (CKD) patients face high cardiovascular risk due to systemic inflammation. Targeting inflammation pathways shows promise for improving both kidney and heart health outcomes in CKD.
Area of Science:
- Nephrology
- Immunology
- Cardiology
Background:
- Chronic kidney disease (CKD) affects 844 million globally, posing a significant public health challenge.
- Systemic inflammation is a key driver of cardiovascular complications in CKD patients.
- Multiple factors contribute to severe inflammation in CKD, including cellular senescence and immune activation.
Purpose of the Study:
- To explore the role of systemic inflammation in CKD progression and cardiovascular events.
- To evaluate the potential of targeting innate immune responses for improved patient outcomes.
- To review existing and emerging therapies aimed at mitigating inflammation in CKD.
Main Methods:
- Analysis of cohort studies linking inflammation biomarkers to CKD progression and cardiovascular events.
- Review of clinical trial data for anti-inflammatory agents in cardiovascular and kidney disease.
- Examination of mechanisms driving inflammation in CKD, such as cellular senescence and immune activation.
Main Results:
- Inflammation biomarkers are strongly associated with increased risk of kidney failure and cardiovascular events in CKD.
- Inhibition of interleukin-1 beta (IL-1β) signaling reduced cardiovascular events in patients with coronary heart disease, including those with CKD.
- Ongoing trials are investigating drugs like ziltivekimab (IL-6 antagonist) for CKD and cardiovascular benefits.
Conclusions:
- Mitigating systemic inflammation is a promising therapeutic strategy for reducing cardiovascular and kidney disease risks in CKD patients.
- Targeting innate immune pathways offers a potential avenue for novel treatments.
- Further research and clinical trials are crucial to validate these anti-inflammatory approaches.
Abstract:
With a global burden of 844 million, chronic kidney disease (CKD) is now considered a public health priority. Cardiovascular risk is pervasive in this population, and low-grade systemic inflammation is an established driver of adverse cardiovascular outcomes in these patients. Accelerated cellular senescence, gut microbiota-dependent immune activation, posttranslational lipoprotein modifications, neuroimmune interactions, osmotic and nonosmotic sodium accumulation, acute kidney injury, and precipitation of crystals in the kidney and the vascular system all concur in determining the unique severity of inflammation in CKD. Cohort studies documented a strong link between various biomarkers of inflammation and the risk of progression to kidney failure and cardiovascular events in patients with CKD. Interventions targeting diverse steps of the innate immune response may reduce the risk of cardiovascular and kidney disease. Among these, inhibition of IL-1β (interleukin-1 beta) signaling by canakinumab reduced the risk for cardiovascular events in patients with coronary heart disease, and this protection was equally strong in patients with and without CKD. Several old (colchicine) and new drugs targeting the innate immune system, like the IL-6 (interleukin 6) antagonist ziltivekimab, are being tested in large randomized clinical trials to thoroughly test the hypothesis that mitigating inflammation may translate into better cardiovascular and kidney outcomes in patients with CKD.
Related Concept Videos
Chronic Kidney Disease II: Clinical Manifestations
Acute Kidney Injury II: Pathophysiology
Chronic Kidney Disease IV: Nursing Management
Kidney Transplant I: Introduction
Nephrotic Syndrome I : Introduction
Acute Kidney Injury IV: Diagnostic Studies and Prevention

